Načítá se...

HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor

Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that lack HER2 gene amplification. These patients are not candidates for HER2 targeted drugs under current standards of care, but preclinical data strongly suggest that these patients will benefit from anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Natl Compr Canc Netw
Hlavní autoři: Ben–Baruch, Noa Efrat, Bose, Ron, Kavuri, Shyam M., Ma, Cynthia X., Ellis, Matthew J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701428/
https://ncbi.nlm.nih.gov/pubmed/26358790
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!